🔗 Share this article Users Coming Off Weight-Loss Medications Gain Back Weight at a Quadrupled Rate Than People Using Diet and Exercise Obesity treatment often requires ongoing approaches. Fresh analysis suggests that individuals who discontinue popular slimming jabs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise programs. Published data in a major medical journal demonstrates that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month upon discontinuation. "Individuals buying such medications need to be informed of the danger of fast rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb. This pace of recovery means a return to starting weight within about one and a half years. Analyzing Treatments The study, which reviewed dozens of studies involving over 9,000 of patients, compared the results of these new drugs with other pills. Researchers point out that individuals who lose weight through diet and exercise usually see a more gradual creep back—around 100 grams monthly—after stopping. Understanding the Rapid Rebound Doctors believe the mechanism of the drugs explains the amplified rebound. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness. "Artificially providing GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher. "Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating a significant risk." A Chronic Disease? Medical guidelines recommend the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes. Many experts argue that, due to the high risk of weight regain, the therapy is often life-long. This perspective is supported by drug manufacturers, who state that the results "underscore the chronic nature of obesity," comparing it to managing conditions like diabetes. User Experiences People who have discontinued the jabs describe a powerful return of hunger. "It was like a switch that goes on and I was suddenly ravenous," said one woman. This challenge is compounded if patients have not adopted permanent lifestyle or habit changes during treatment. Growing Adoption Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with desire being substantial. Adoption is greater among women compared to males. The middle-aged age group shows the highest usage rates. A large proportion obtain the drugs through private healthcare rather than the NHS. In conclusion, clinicians caution that while these medications are powerful agents for shedding pounds, they are not a permanent solution and long-term success likely depends on combined behavioural management.
Obesity treatment often requires ongoing approaches. Fresh analysis suggests that individuals who discontinue popular slimming jabs like semaglutide or tirzepatide may regain shed pounds at a significantly accelerated pace than those who halt traditional diet and exercise programs. Published data in a major medical journal demonstrates that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month upon discontinuation. "Individuals buying such medications need to be informed of the danger of fast rebound weight gain when the treatment is stopped," stated researcher Dr. Susan Jebb. This pace of recovery means a return to starting weight within about one and a half years. Analyzing Treatments The study, which reviewed dozens of studies involving over 9,000 of patients, compared the results of these new drugs with other pills. Researchers point out that individuals who lose weight through diet and exercise usually see a more gradual creep back—around 100 grams monthly—after stopping. Understanding the Rapid Rebound Doctors believe the mechanism of the drugs explains the amplified rebound. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls feelings of fullness. "Artificially providing GLP-1 levels several times higher than the body's typical production may cause the system to produce less of its own natural GLP-1, and may also diminish sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher. "Withdrawal of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating a significant risk." A Chronic Disease? Medical guidelines recommend the injections for individuals with obesity-related health risks, alongside recommended lifestyle changes. Many experts argue that, due to the high risk of weight regain, the therapy is often life-long. This perspective is supported by drug manufacturers, who state that the results "underscore the chronic nature of obesity," comparing it to managing conditions like diabetes. User Experiences People who have discontinued the jabs describe a powerful return of hunger. "It was like a switch that goes on and I was suddenly ravenous," said one woman. This challenge is compounded if patients have not adopted permanent lifestyle or habit changes during treatment. Growing Adoption Survey data suggest that a significant number of adults in the UK have tried these injections in the past year, with desire being substantial. Adoption is greater among women compared to males. The middle-aged age group shows the highest usage rates. A large proportion obtain the drugs through private healthcare rather than the NHS. In conclusion, clinicians caution that while these medications are powerful agents for shedding pounds, they are not a permanent solution and long-term success likely depends on combined behavioural management.